Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials Date: insert date here Client: Insert Client here Summary: April 23, 2011 (Calgary, AB) - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announces the "Mechanism of Action" (MoA) by which RVX-208 increases apolipoprotein A-I (ApoA-I) production. Our data shows RVX-208 to be an inhibitor of the Bromodomain and Extraterminal Domain (BET) proteins. RVX-208 acts on BET proteins, including BRD4, a member of the BET-protein family, leading to increased transcription of the ApoA-I gene followed by production of more ApoA-I protein.
		OrbusNeich Hosts Symposium at Angioplasty Summit TCTAP 2012: "The Next Era: Combo Dual Therapy Stent" Date: April 22, 2012 Client: OrbusNeich Summary: HONG KONG, April 22, 2012 - OrbusNeich will host a lunch symposium featuring the Combo Dual Therapy Stent at the Angioplasty Summit TCTAP 2012 in Seoul, Korea, entitled "The Next Era: Combo Dual Therapy Stent." The event will be chaired by Drs. Seung Jung Park and Harry Suryapranata.
		OrbusNeich's Genous Stent Achieves Complete Endothelialization at Two Weeks Date: April 20, 2012 Client: OrbusNeich Summary: HONG KONG, April 20, 2012 - OrbusNeich today announced that optical coherence tomography (OCT) results published in the April edition of the Journal of Invasive Cardiology show that the Genous Stent achieves full strut coverage and endothelialization two weeks after percutaneous coronary intervention (PCI). The case report features OCT images of a patient who underwent PCI in advance of a non-deferrable surgery for stomach cancer and who safely discontinued dual antiplatelet therapy (DAPT) at two weeks following revascularization.
		ACT Announces Third Dry AMD Patient Treated in Clinical Trial Date: Apr 20, 2012 Client: Advanced Cell Technology, Inc. Summary: MARLBOROUGH, Mass., Apr 20, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today the dosing of the third patient in its Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The outpatient transplantation surgery was performed successfully, and the patient is recovering uneventfully.
		MolecularHealth's Use of Clinico-Molecular Informatics for Oncology Treatment Decision Support Presented at Meeting of Nation's Leading Clinical Research Physicians Date: MolecularHealth Client: April 19, 2012 Summary: SAN FRANCISCO, April 19, 2012 - MolecularHealth, a leader in clinico-molecular informatics, today announced that Stephan Brock, Ph.D., the company's president, showcased the use of clinico-molecular informatics for oncology treatment decision support at the SWOG Spring 2012 Group Meeting in San Francisco. SWOG (formerly Southwest Oncology Group) is one of the five cooperative groups that together comprise the National Cancer Institute's (NCI's) National Clinical Trials Network. Each year, SWOG hosts two Group Meetings to review progress made towards findings cures for cancer and to determine future directions. MolecularHealth was the only company invited to present at this semiannual event, which hosted around 1,000 of the nation's leading clinical research oncologists.
		Alder BioPharmaceuticals Inc. Closes $38 Million Series D Financing to Accelerate Clinical Development of its Pipeline of Antibody Therapeutics Date: April 19, 2012 Client: Alder BioPharmaceuticals Inc. Summary: BOTHELL, Wash., April 19, 2012 /PRNewswire/ -- Alder BioPharmaceuticals Inc. today announced the closing of a $38 million Series D financing to support the development of the company's clinical stage pipeline. The financing was led by a new investor, Novo Ventures, and joined by existing Alder investors Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech. Peter Bisgaard, a partner with Novo Ventures, will join Alder's board of directors.
		Merck To Pay Up To $1B To Endocyte For Experimental Cancer Drug Date: April 16, 2012 Client: Endocyte Inc. Summary: Merck & Co. (MRK) has agreed to pay $120 million upfront to Endocyte Inc. (ECYT), with additional payouts of up to $880 million, to develop and market the experimental cancer drug vintafolide as the drug maker looks to bring more drugs to market.
		Endocyte soars on cancer drug deal with Merck Date: April 16, 2012 Client: Endocyte Inc. Summary: April 16 (Reuters) - Merck & Co Inc said it acquired the development and marketing rights to Endocyte Inc's experimental cancer drug for $120 million in cash and up to $880 million in milestone payments.
		Ambit Biosciences to Present at the 19th Annual Future Leaders in the Biotech Industry Conference Date: April 16, 2012 Client: Ambit Biosciences Summary: SAN DIEGO, April 16, 2012 /PRNewswire via COMTEX/ -- Ambit Biosciences today announced that the company is scheduled to present at the 19th Annual Future Leaders in the Biotech Industry Conference at 8:30 a.m. EDT on Friday, April 20, 2012, at the Millennium Broadway Hotel in New York City. Michael A. Martino, Ambit's president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib.
		ACT Announces Second Patient with Dry AMD Treated in U.S. Clinical Trial with RPE Cells Derived from Embryonic Stem Cells Date: April 16, 2012 Client: Advanced Cell Technology, Inc. Summary: MARLBOROUGH, Mass., Apr 16, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the second patient was dosed in the Company's Phase I/II trial for dry age-related macular degeneration (dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient is recovering uneventfully.
		Merck and Endocyte Enter Exclusive Worldwide Agreement to Develop and Commercialize Phase III Cancer Candidate Vintafolide (EC145) Date: April 16, 2012 Client: Endocyte Inc. Summary: WHITEHOUSE STATION N.J. & WEST LAFAYETTE, Ind., Apr 16, 2012 (BUSINESS WIRE) -- Merck, known as MSD outside the United States and Canada, and Endocyte Inc., today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145). Vintafolide is currently being evaluated in a Phase III clinical trial for platinum-resistant ovarian cancer, (PROCEED trial) and a Phase II trial for non-small cell lung cancer (NSCLC); both studies are also using Endocyte's investigational companion diagnostic agent, etarfolatide (EC20).
		Advanced Cell Technology to Webcast 2012 Annual Shareholders' Meeting on April 26th Date: April 13, 2012 Client: Advanced Cell Technology, Inc. Summary: MARLBOROUGH, Mass., Apr 13, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will webcast its Annual Shareholders’ Meeting to be held on Thursday, April 26th at the Hyatt Regency Suites, Palm Springs, 285 N. Palm Canyon Drive, Palm Springs, Calif. The meeting is open to shareholders of record as of March 1, 2012. The webcast will begin at 9 a.m. PDT, after the Company completes the formal portion of the meeting, where results of proxy voting will be announced. At that time, members of the management team will deliver a Company presentation and address questions from shareholders. Questions will be taken from shareholders in attendance as well as electronically from the webcast.
		More Than $224 Million Raised by U.S. Life Sciences Companies Through At-The-Market (ATM) Offerings in 2011 vs. $184 Million in 2010, Brinson Patrick Reports Date: April 10, 2012 Client: Brinson Patrick Securities Corporation Summary: NEW YORK, April 10, 2012 - Brinson Patrick Securities Corporation, a boutique investment bank specializing in at-the-market (ATM) offerings, announced today that life sciences companies in the U.S. raised more than $224 million through ATMs in 2011, compared to $184 million in 2010, a 22 percent year-over year increase.
		More Biotech Firms Head to ATM for Cash Date: April 9, 2012 Client: Brinson Patrick Securities Corporation Summary: Publicly held biotechnology companies are increasingly going the ATM route to raise capital, said Todd Wyche, co-founder and managing director of New York-based investment firm Brinson Patrick Securities Corp., which has an office in La Jolla.
		AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 Weeks Compared to Placebo in Phase IIb Trial for the Treatment of Duchenne Muscular Dystrophy Date: April 2, 2012 Client: AVI BioPharma, Inc. Summary: BOTHELL, WA, Apr 02, 2012 (MARKETWIRE via COMTEX) -- AVI BioPharma, Inc., a developer of RNA-based therapeutics, today announced that treatment with eteplirsen met the primary efficacy endpoint in a randomized, double-blind, placebo-controlled Phase IIb study in boys with Duchenne muscular dystrophy (DMD). Eteplirsen administered once weekly at 30mg/kg over 24 weeks resulted in a statistically significant (p = 0.002) increase in novel dystrophin (22.5% dystrophin-positive fibers as a percentage of normal) compared to no increase in the placebo group.